The antibody clone M79 is directed to human tumor antigens, preferably to the human tumor antigen 17-1A, also known as EpCAM, EGP or GA 733-2.
Figure 1 Isolation of proteins from cell and tissue lysates by affnity chromatography using M79- and Con A-sepharose columns.
By affnity chromatography using M79-sepharose column, a 33-kDa protein (P33) was isolated from HCT cell lysates. Moreover, a 50-kDa protein (P50) was isolated from lysates of human colorectal tumor tissues. A 65-kDa protein (P65) was also found by affnity chromatography using Con A-sepharose column and then M79-sepharose column.
Chen, Y. H., Yu, T., Bai, Y., & Zhao, N. (1999). Two proteins share immunological epitopes on the tumor-associated antigen 17-1A. Cancer letters, 144(1), 101-105.
Figure 2 Identification of interaction of mAbs 17-1A and M79 with the isolated proteins by ELISA.
a: A, mAb 17-1A binding to P33; B, mAb M79 binding to P33. b: A, mAb 17-1A binding to P50; B, mAb M79 binding to P50. c: mAb 17-1A binding to P65; B, mAb M79 binding to P65. Control: gelatine instead of these antigens by coating the microtiter plate.
Chen, Y. H., Yu, T., Bai, Y., & Zhao, N. (1999). Two proteins share immunological epitopes on the tumor-associated antigen 17-1A. Cancer letters, 144(1), 101-105.
Figure 3 Inhibition of mAb 17-1A (a) and M79 (b) binding to HT-29 cells by P50, in flow cytometry analysis.
P50 showed an enhancement effect on the binding of both mAbs.
Chen, Y. H., Yu, T., Bai, Y., & Zhao, N. (1999). Two proteins share immunological epitopes on the tumor-associated antigen 17-1A. Cancer letters, 144(1), 101-105.
Figure 4 Inhibition of mAb 17-1A (a) and M79 (b) binding to HT-29 cells by P65, in flow cytometry analysis.
P65 did not inhibit the binding of mAb 17-1A to HT-29 cells, and on the contrary, could weakly up-modulate the binding of M79.
Chen, Y. H., Yu, T., Bai, Y., & Zhao, N. (1999). Two proteins share immunological epitopes on the tumor-associated antigen 17-1A. Cancer letters, 144(1), 101-105.
This is a product of Creative Biolabs' Hi-Affi™ recombinant antibody portfolio, which has several benefits including:
• Increased sensitivity
• Confirmed specificity
• High repeatability
• Excellent batch-to-batch consistency
• Sustainable supply
• Animal-free production
See more details about Hi-Affi™ recombinant antibody benefits.
Download resources about recombinant antibody development and antibody engineering to boost your research.
Select a product category from the dropdown menu below to view related products.
CAT | Product Name | Application | Type |
---|---|---|---|
AGTO-L013E | anti-EPCAM immunotoxin MOC31 (IgG)-PE | Cytotoxicity assay, Functional assay | |
AGTO-L013D | anti-EPCAM immunotoxin MOC31 (IgG)-DT | Cytotoxicity assay, Functional assay | |
AGTO-L013G | anti-EPCAM immunotoxin MOC31 (IgG)-Gel | Cytotoxicity assay, Functional assay | |
AGTO-L013R | anti-EPCAM immunotoxin MOC31 (IgG)-RTA | Cytotoxicity assay, Functional assay | |
AGTO-L013O | anti-EPCAM immunotoxin MOC31 (IgG)-Bouganin | Cytotoxicity assay, Functional assay |
There are currently no Customer reviews or questions for HPAB-S0025-YC. Click the button above to contact us or submit your feedback about this product.
For Research Use Only. Not For Clinical Use.
For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.